For example, TG2 mediates NF-κB activation, interleukin-6 (IL-6) upregulation, and Janus kinase/ signal transducer and activator of transcription 3 (JAK/STAT3) induction, thus promoting tumor progression, the acquisition of a stem-like phenotype, and neratinib resistance [37]. This evidence concerns the gene NFKB1 and neoplasm.